In a bid to extend radiation oncology applications, engineers at Philips Healthcare have widened the bore of the company’s premium Gemini TF PET/CT scanner to create the industry’s first big-bore hybrid. Priced north of $2 million, the Gemini TF Big Bore is scheduled to begin shipping next year. Philips is showcasing the Big Bore this week on the RSNA exhibit floor, and beta testing will begin at the University of Pennsylvania Hospital in the next several months.
In a bid to extend radiation oncology applications, engineers at Philips Healthcare have widened the bore of the company's premium Gemini TF PET/CT scanner to create the industry's first big-bore hybrid. Priced north of $2 million, the Gemini TF Big Bore is scheduled to begin shipping next year. Philips is showcasing the Big Bore this week on the RSNA exhibit floor, and beta testing will begin at the University of Pennsylvania Hospital in the next several months.
Philips' proprietary TruFlight time-of-flight technology, which characterizes the Gemini TF, allowed the company to widen the bore from 71.7 cm to 85 cm without compromising image quality or scan time, according to the company. The new system offers a combination of accessories and localization devices designed specifically for use in radiation oncology. Its large bore meets treatment planning requirements for patients who must be scanned in extended positions, as in cases of breast and colorectal scanning, by allowing them to be positioned for simulation in the same manner as they would be positioned to receive therapy.
Precise measurements are particularly important in radiation treatment planning. Toward that end, the company has integrated a more rigid table than the one used on the conventional Gemini PET/CT, providing very precise localization based on rigid patient framing.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.